| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $5.4M | -36.1% | -56.3% |
| SG&A Expense | $2.6M | +54.5% | -30.5% |
| Operating Income | -$8.0M | +21.3% | +50.4% |
| Net Income | -$7.7M | +21.3% | +49.1% |
| EPS (Basic) | -$0.13 | +18.8% | +48.0% |
| EPS (Diluted) | -$0.13 | +18.8% | +48.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $59.3M | +43.9% | -12.9% |
| Short-term Investments | $16.0M | -60.8% | -64.2% |
| Current Assets | $77.5M | -8.4% | -33.6% |
| Total Assets | $77.8M | -8.4% | -33.7% |
| Current Liabilities | $28.5M | -3.5% | +66.1% |
| Long-term Debt |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$28.0M | — | — |
| Investing Cash Flow | $31.7M | — | — |
| Financing Cash Flow | $1.1M | — | — |
| $15.3M |
| +0.0% |
| -1.9% |
| Total Liabilities | $28.6M | -3.8% | -11.4% |
| Stockholders' Equity | $49.2M | -10.9% | -42.1% |